Andrew W. Mulcahy

Photo of Andrew Mulcahy
Senior Policy Researcher
Washington Office

Education

Ph.D. in health care management and economics, The Wharton School; M.P.P. in health policy, The Johns Hopkins University; A.B. in molecular biology and public policy, Princeton University

Overview

Andrew Mulcahy is a senior policy researcher at the RAND Corporation. His key research areas are prescription drugs, payment for health care services and drugs, and policy evaluation in general and particularly evaluation of Affordable Care Act (ACA) provisions.  He routinely uses large-scale health care claims and transactional data in his research. 

Mulcahy leads projects using Medicare and other health care claims and encounter data to answer research questions related to health insurance coverage, insurance benefit design, payment for health care services, and other health policy topics. In the area of payment, Mulcahy's recent research focuses on the accurate valuation of services under the Resource-Based Relative Value Scale system used by Medicare and many other payers to pay practitioners. In prescription drugs, Mulcahy is the lead author on a set of RAND Perspectives outlining key policy issues around the 340B Drug Discount Program and biosimilars.

Mulcahy's portfolio also includes analyses of the U.S. blood system and ground ambulance industry. More broadly, Mulcahy's research at RAND has touched on policy issues around specialty drugs, value in health care, and incentives for innovation in health.

Mulcahy earned his Ph.D. from the University of Pennsylvania's Wharton School Health Care Management and Economics program, his M.P.P. at the Johns Hopkins University with a concentration in health policy, and his A.B. in molecular biology and public policy at Princeton University.

Commentary

  • Volunteers in protective suits disinfect a railway station as China tries to contain an outbreak of coronavirus, Changsha, Hunan province, February 4, 2020, photo by Stringer/Reuters

    Coronavirus Outbreak Intensifies: Q&A with RAND Experts

    Cases of the coronavirus have now spread to several dozens of countries, infecting thousands and thousands of people across the globe. With concerns about the disease rising, we asked a group of RAND researchers to answer a wide range of questions about the crisis.

    Mar 5, 2020

  • A variety of prescription pills and capsules formed into a dollar sign, photo by ADragan/Getty Images

    The Promise and Peril of Offshoring Prescription Drug Pricing

    Most Americans, including Congress and the president, agree that prescription drug prices are too high. Policy proposals from both major parties could promise some relief. Several of them look to drug prices in other countries to help set prices in the United States.

    Sep 16, 2019 The Hill

  • White prescription pills on a U.S. $100 bill, photo by Stuart Ritchie/Getty Images

    Price-Fixing Case Reveals Vulnerability of Generic Drug Policies

    A massive lawsuit filed by 44 states accuses 20 major drug makers of colluding to inflate prices on more than 100 generic drugs, including HIV, cancer, and depression treatments. If these allegations are true, then this isn't just a violation of antitrust law. It's a betrayal of the policies that created and defended the entire generic drug industry.

    Jul 15, 2019 The Health Care Blog

  • A woman is wheeled through an emergency department on a gurney.

    Covering Emergency Care for Young Adults: Is the ACA Doing Its Job?

    The dependent coverage provision of the Affordable Care Act is working as intended, say Andrew Mulcahy and Katherine Harris. In 2011, it spared individuals and hospitals from $147 million in emergency room costs.

    Jun 5, 2013

Publications

Multimedia